Glaukos (NYSE:GKOS) Upgraded by Jefferies Financial Group to Buy

Jefferies Financial Group upgraded shares of Glaukos (NYSE:GKOS) from a hold rating to a buy rating in a report published on Monday, MarketBeat.com reports. Jefferies Financial Group currently has $125.00 price target on the medical instruments supplier’s stock, up from their prior price target of $84.00.

Other equities research analysts have also issued research reports about the stock. Mizuho lifted their price objective on shares of Glaukos from $85.00 to $100.00 and gave the company a neutral rating in a report on Thursday, April 11th. Citigroup upped their price target on shares of Glaukos from $107.00 to $120.00 and gave the company a buy rating in a report on Monday, March 25th. StockNews.com lowered Glaukos from a hold rating to a sell rating in a research note on Tuesday, February 27th. JPMorgan Chase & Co. upped their target price on Glaukos from $108.00 to $110.00 and gave the stock an overweight rating in a research note on Thursday, May 2nd. Finally, Stifel Nicolaus reiterated a buy rating and issued a $110.00 target price on shares of Glaukos in a research note on Wednesday, April 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $108.64.

Glaukos Trading Down 0.4 %

Shares of NYSE:GKOS traded down $0.41 during trading hours on Monday, hitting $104.60. 14,989 shares of the company’s stock traded hands, compared to its average volume of 644,982. The company has a quick ratio of 4.68, a current ratio of 5.38 and a debt-to-equity ratio of 0.78. The business has a fifty day moving average price of $93.59 and a 200-day moving average price of $83.34. Glaukos has a 1 year low of $54.38 and a 1 year high of $110.73.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.12). Glaukos had a negative net margin of 43.15% and a negative return on equity of 24.69%. The business had revenue of $85.60 million for the quarter, compared to analysts’ expectations of $79.60 million. During the same quarter in the previous year, the firm earned ($0.59) EPS. Glaukos’s revenue was up 15.8% compared to the same quarter last year. Equities research analysts anticipate that Glaukos will post -2.2 earnings per share for the current fiscal year.

Insider Transactions at Glaukos

In related news, CFO Alex R. Thurman sold 474 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $90.37, for a total transaction of $42,835.38. Following the completion of the transaction, the chief financial officer now owns 54,916 shares of the company’s stock, valued at approximately $4,962,758.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Glaukos news, Director Mark J. Foley sold 4,560 shares of the company’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $92.87, for a total transaction of $423,487.20. Following the sale, the director now owns 33,220 shares in the company, valued at approximately $3,085,141.40. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Alex R. Thurman sold 474 shares of the business’s stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $90.37, for a total value of $42,835.38. Following the transaction, the chief financial officer now directly owns 54,916 shares of the company’s stock, valued at $4,962,758.92. The disclosure for this sale can be found here. Insiders sold 235,382 shares of company stock worth $22,229,471 in the last 90 days. Insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Glaukos

A number of hedge funds and other institutional investors have recently modified their holdings of GKOS. Brown Capital Management LLC raised its position in shares of Glaukos by 3.4% during the 4th quarter. Brown Capital Management LLC now owns 2,697,794 shares of the medical instruments supplier’s stock worth $214,448,000 after acquiring an additional 89,420 shares in the last quarter. Fred Alger Management LLC lifted its position in shares of Glaukos by 9.2% during the 3rd quarter. Fred Alger Management LLC now owns 1,780,690 shares of the medical instruments supplier’s stock worth $133,997,000 after buying an additional 150,102 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Glaukos by 45.5% in the 3rd quarter. Invesco Ltd. now owns 1,450,033 shares of the medical instruments supplier’s stock valued at $109,115,000 after buying an additional 453,756 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Glaukos by 3.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 923,526 shares of the medical instruments supplier’s stock valued at $73,412,000 after acquiring an additional 31,213 shares during the last quarter. Finally, Primecap Management Co. CA boosted its stake in Glaukos by 23.7% in the fourth quarter. Primecap Management Co. CA now owns 790,035 shares of the medical instruments supplier’s stock valued at $62,800,000 after acquiring an additional 151,415 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.